This potential connection between body mass reduction and improved clinical outcomes for patients with obesity-related HFpEF has been tested in randomized controlled trials of the glucagon-like peptide 1 agonist and supported by the results of a recent study demonstrating that treatment with semaglutide 2.4 mg weekly led to larger reductions in symptomatic and physical burdens, greater improvements in functional capacity than placebo in patients with HFpEF and obesity [34]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.